完全ヒト抗体/ TCRプラットフォーム

二重特異性抗体

二重特異性抗体(BsAb)は、2つの抗原を同時に標的とすることで、特異性の向上、耐性の克服、疾患の異質性への対処を可能にするという独自の利点を有しています。薬物動態を最適化し、オフターゲット効果を低減し、経路遮断や免疫細胞のリダイレクトといった多様なメカニズムをサポートすることで、幅広い治療の可能性を解き放ちます。
  • 複数の腫瘍駆動型タンパク質を同時にターゲットにできることで、薬物耐性を克服する可能性があります。
  • 両方のターゲットを共発現する細胞を認識することで、腫瘍特異性が高まり、オフターゲット毒性が減少します。
  • 2つの選択されたターゲットの組み合わせにより、内因性が増加し、腫瘍の死滅が促進されます。
  • 10+
    完全ヒト型二重特異性抗体
  • 10+
    TCRミミックアセット

このページで

  • BsAbプラットフォームの特徴
  • RenLiteベースのBsAbプラットフォーム
  • 現在利用可能なBsAbs
  • FAQs

ウェビナー

すべて表示

    ポスター

    すべて表示

      BsAbプラットフォームの特徴

      • 多機能設計:Knobs-into-Holesなどの技術を利用して、scFv、ペプチド、VHH、サイトカインなどの多様なコンポーネントを柔軟に組み立てることができます。
      • 共通軽鎖の利点:誤対合を最小限に抑えながら、効率的かつ正確な二重特異性アセンブリを実現する完全ヒト共通軽鎖抗体を生成します。
      • 高品質の抗体:RenLite KOマウスとBeacon技術を組み合わせることで、卓越した多様性と親和性を持つ抗体を生成します。
      • スケーラブルな検証:強力なin vivoシステムを使用して、有効で安全なターゲット組み合わせを特定します。
      • 二機能性分子:優れた相乗効果を持つ抗体-サイトカイン分子を開発し、サイトカインベースの治療法の薬物化可能性を高めます。

      RenLiteベースのBsAbプラットフォーム

      RenLiteマウスから開発されたBsAb

      BsAb developed from RenLite mice

      現在利用可能なBsAbs

      Format Therapeutic Area Product Number Target(s) Immunization
      • Development
      • Hits
        selection
        Leads
        selection
        Candidate
        selection
      Preclinical IND Phase I Status
      BsAb Oncology YH008 PD-1 x CD40
      Partnered ex-China rights available
      BsAb Oncology YH006 OX40 x CTLA4
      BsAb Oncology BCG021 4-1BB x CD40
      BsAb Inflammation and Autoimmunity BCG028 OX40 x OX40
      BsAb Oncology - CD40 x CTLA4
      BsAb Oncology BCG051 GDF15 x VEGFA
      BsAb Inflammation and Autoimmunity - IL4RA x KIT
      BsAb Inflammation and Autoimmunity - IL13 x TSLP
      BsAb Inflammation and Autoimmunity - IL17A x IL17F x IL4RA
      BsAb Oncology - B7-H3 x FN1
      TCE Oncology - CDH17 x CD3 x CD28
      TCE Oncology - STEAP1 x CD3e
      TCE Oncology BCG024 DLL3 x CD3 x 4-1BB
      Tri-Ab Oncology BCG038 EGFR x VEGFA x CD98
      Tri-Ab Oncology - PD-L1 x CD98 x VEGFA
      Tri-Ab Inflammation and Autoimmunity - C2 x FCGRT x ALB
      Tri-Ab Oncology - PD-L1 x IL11 x VEGFA
      Tri-Ab Oncology - PD-L1 x VEGFA x IL27R

      Frequently Asked Questions (FAQs) About Bispecific Antibody Platform

      1. What is a bispecific antibody, and what unique mechanisms of action does it offer beyond conventional monoclonal antibodies?

      A bispecific antibody (BsAb) recognizes two different antigens or epitopes within a single molecule. This dual specificity enables novel therapeutic mechanisms beyond conventional monospecific antibodies, including: dual pathway blockade, receptor co-localization or clustering, and immune-cell redirection such as T-cell engagers (TCEs).

      2. What antibody formats and modalities does Biocytogen’s bispecific antibody platform support?

      Biocytogen’s platform supports fully human bispecific, biparatopic, and multispecific antibody formats. Flexible architectures can incorporate common light chain antibodies, VHHs, scFvs and cytokines to meet diverse therapeutic design needs. In addition to unconjugated BsAbs and BpAbs, Biocytogen has also established a platform that enables selected bispecific antibody backbones to be further developed into bispecific antibody-drug conjugates (BsADCs).

      3. What are the advantages of developing biparatopic antibodies (BpAbs)?

      BpAbs bind two distinct, non-overlapping epitopes on the same antigen to overcome the limitations of conventional monoclonal antibodies. Key advantages include:
      • Enhanced target engagement: Achieves greater receptor occupancy and more complete ligand blockade compared with single-epitope antibodies.
      • Differentiated functional activity: Modulation of receptor clustering, internalization, or signaling to enhance therapeutic activity.
      For example, Biocytogen’s BCG028, a biparatopic OX40 antagonist, leverages dual-epitope binding to reduce OX40-mediated T-cell costimulatory signaling, delivering superior in vivo efficacy in preclinical models.

      4. How does Biocytogen address chain mispairing in bispecific antibody generation?

      Biocytogen combines complementary engineering strategies to simplify fully human bispecific and multispecific antibody assembly:
      • RenLite®-derived common light-chain antibodies: Use a shared light chain to avoid mispairing between different heavy and light chains.
      • Fully human VHH antibody integration: Provide compact, modular single-domain building blocks that require no light chain, reducing pairing complexity.
      • Knobs-into-Holes (KIH) engineering: Applied to promote correct pairing between two different heavy chains.
      Together, these approaches address distinct chain-pairing challenges, simplifying antibody assembly and supporting favorable developability.

      5. How does Biocytogen discover and evaluate fully human bispecific antibody candidates?

      Biocytogen uses RenLite® or RenLite® target-gene KO mice to generate fully human common light-chain antibodies. Beacon-based single-cell screening with AI-powered selection supports accelerated candidate identification. Candidates are then evaluated in in vivo studies, including target-humanized mouse models, to assess efficacy and safety with high translational potential.

      6. What off-the-shelf antibody libraries does Biocytogen offer for bispecific antibody development?

      Biocytogen offers more than 200 TAA-specific fully human antibody backbones for plug-and-play bispecific antibody (BsAb) development. Through RenSuper™ Workstation, partners can also access broader antibody libraries spanning over 1,000 targets to identify building blocks for customized and scalable BsAb development.